NCT03651102View on ClinicalTrials.gov

Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

654

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

March 1, 2022

Conditions
Thalassemia
Interventions
DRUG

Thalidomide and Hydroxyurea

Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day

Trial Locations (1)

0000

Blood Diseases Clinic, Peshawar

All Listed Sponsors
collaborator

University of Peshawar

OTHER

lead

Blood Diseases Clinic

OTHER

NCT03651102 - Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia | Biotech Hunter | Biotech Hunter